The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS: We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS: As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Wells G, 2008, Cochrane Database Syst Rev, 1, CD004523
- Martin TJ, 2004, J Musculoskelet Neuronal Interact, 4, 243
Cited by
Sorted by citations
Items 701–800 of 1,006
Ungprasert, P., Cheungpasitporn, W., Srivali, N., Kittanamongkolchai, W., & Bischof, E. F. (2013) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2012.11.011 · Cited by 49
Health Technology Assessment in Osteoporosis
Hiligsmann, M., Kanis, J. А., Compston, J. E., Cooper, C. C., Flamion, B., Bergmann, P., Body, J., Boonen, S., Bruyère, O., Devogelaer, J., et al. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9724-8 · Cited by 47
Osteoporosis in chronic obstructive pulmonary disease
Romme, E. A., Smeenk, F. W. J. M., Rutten, E. P. A., & Wouters, E. F. �. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.814402 · Cited by 50
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Raje, N. S., & Yee (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s14566 · Cited by 49
Bioactive silica nanoparticles reverse age-associated bone loss in mice
Weitzmann, M. N., Ha, S., Vikulina, T., Roser‐Page, S., Lee, J.-K., & Beck, G. R. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.01.013 · Cited by 49
Li, J., Zeng, L., Xie, J., Yue, Z., Deng, H., Ma, X., Zheng, C., Wu, X., Luo, J., & Liu, M. (2015) · Scientific Reports · doi:10.1038/srep17605 · Cited by 50
Sebastián, J. V. B., Peydró, A., Calvo, J., Leopoldo, M., Jiménez, Y., & Bagán, L. (2016) · Oral Diseases · doi:10.1111/odi.12447 · Cited by 49
Osteoporosis treatment: a missed opportunity
Milat, F., & Ebeling, P. R. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00568 · Cited by 50
Denosumab is effective in the treatment of bone marrow oedema syndrome
Rolvien, T., Schmidt, T., Butscheidt, S., Amling, M., & Barvencik, F. (2017) · Injury · doi:10.1016/j.injury.2017.02.020 · Cited by 49
Medication-Related Osteonecrosis of the Jaws
Migliorati, C. A., Brennan, M. T., & Peterson, D. E. (2019) · JNCI Monographs · doi:10.1093/jncimonographs/lgz009 · Cited by 49
Chen, J., Hsu, C., Yu, S., Ko, C., Chiu, W.-C., Lai, H., Chen, Y., Su, Y., & Cheng, T. (2019) · Rheumatology · doi:10.1093/rheumatology/kez655 · Cited by 50
Bone changes in alcoholic liver disease
González-Reimers, E. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i9.1258 · Cited by 48
Meier, M. E., Clerkx, S. N., Winter, E. M., Pereira, A. M., van de Ven, A. C., van de Sande, M. A. J., & Appelman‐Dijkstra, N. M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4380 · Cited by 48
Mou, K., Chan, S. M. H., & Vlahos, R. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108635 · Cited by 53
Zhou, Z., Chen, C., Zhang, J., Ji, X., Liu, L., Zhang, G., Cao, X., & Wang, P. (2014) · PubMed Central · Cited by 48
Adverse drug reactions to osteoporosis treatments
Rizzoli, R., & Reginster, J. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.42 · Cited by 50
Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women
López‐González, Á. A., Grases, F., Fuenmayor, N. M., Marí, B., Vicente-Herrero, M. T., Tur, F., & Perelló, J. (2012) · European Journal of Nutrition · doi:10.1007/s00394-012-0377-6 · Cited by 48
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 49
Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review
Bridgeman, M. B., & Pathak, R. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.008 · Cited by 48
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 48
Denosumab osteonecrosis of the mandible: A new entity?A case report
Pichardo, S. E. C., Kuypers, S. C. C., & van Merkesteyn, J. P. R. (2012) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2012.10.014 · Cited by 48
Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis
Songpatanasilp, T., Sritara, C., Kitisomprayoonkul, W., Chaiumnuay, S., Nimitphong, H., Charatcharoenwitthaya, N., Pongchaiyakul, C., Namwongphrom, S., Kitumnuaypong, T., Srikam, W., et al. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.10.002 · Cited by 50
Cafiero, C., Gigante, M., Brunetti, G., Simone, S., Chaoul, N., Oranger, A., Ranieri, E., Colucci, S. C., Pertosa, G. B., Grano, M., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx222 · Cited by 48
Ide, M., Yamada, K., Kaneko, K., Sekiya, T., Kanai, K., Higashi, T., & Saito, T. (2018) · Orthopaedics & Traumatology Surgery & Research · doi:10.1016/j.otsr.2018.07.015 · Cited by 48
on the behalf of the Study group, Esposti, L. D., Girardi, A. M., Saragoni, S., Sella, S., Andretta, M., Rossini, M., & Giannini, S. (2018) · Endocrine · doi:10.1007/s12020-018-1824-9 · Cited by 48
Rizzoli, R., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3244 · Cited by 48
Chen, C., Chen, N.-C., Liang, H., Hsu, C., Chou, K.-J., Fang, H.-C., & Lee, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1259 · Cited by 47
Cooper, C. C., Reginster, J., Cortet, B., Díaz Curiel, M., Lorenc, R. S., Kanis, J. А., & Rizzoli, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.663750 · Cited by 47
Management of beta‐thalassemia–associated osteoporosis
Giusti, A., Pinto, V. M., Forni, G. L., & Pilotto, A. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13041 · Cited by 47
Metabolomics-based profiles predictive of low bone mass in menopausal women
Miyamoto, T. K., Hirayama, A., Sato, Y., Koboyashi, T., Katsuyama, E., Kanagawa, H., Fujie, A., Morita, M., Watanabe, R., Tando, T., et al. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.06.004 · Cited by 46
Bone management in hematologic stem cell transplant recipients
Kendler, D. L., Body, J., Brandi, M. L., Broady, R. C., Cannata-Andía, J. B., Cannata‐Ortiz, J., Maghraoui, A. E., Guglielmi, G., Hadji, P., Pierroz, D. D., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4669-4 · Cited by 47
Effect of Denosumab on Falls, Muscle Strength, and Function in Community‐Dwelling Older Adults
Phu, S., Hassan, E. B., Vogrin, S., Kirk, B., & Duque, G. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16165 · Cited by 47
Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
Dempster, D. W., Chines, A. A., Bostrom, M. P., Nieves, J. W., Zhou, H., Chen, L., Pannacciulli, N., Wagman, R. B., & Cosman, F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4006 · Cited by 47
Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today?
Ringe, J. D. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00842-0 · Cited by 49
Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management
Kün‐Darbois, J., & Fauvel, F. (2020) · Morphologie · doi:10.1016/j.morpho.2020.11.008 · Cited by 47
Lan, G.-B., Xie, X.-B., Peng, L.-K., Liu, L., Song, L., & Dai, H.-L. (2015) · BioMed Research International · doi:10.1155/2015/413169 · Cited by 46
Past, Present, and Future of Antifungal Drug Development
Shukla, P. K., Singh, P., Yadav, R. K., Pandey, S., & Bhunia, S. S. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_4 · Cited by 48
Osteoporosis after spinal cord injury: aetiology, effects and therapeutic approaches.
Abdelrahman, S., Ireland, A., Winter, E. M., Purcell, M., & Coupaud, S. (2021) · PubMed Central · Cited by 45
Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing
Kushchayeva, Y. S., Pestun, I., Kushchayev, S. V., Radzikhovska, N., & Lewiecki, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247477 · Cited by 49
VARENNA, M., Bertoldo, F., Monaco, M., Giusti, A., Martini, G., Rossini, M., SIOMMMS, O. B. O., & Endorsed by, S. I. R. (2013) · Reumatismo · doi:10.4081/reumatismo.2013.143 · Cited by 47
Current and future treatment options in osteoporosis
Brewer, L., Williams, D. J., & Moore, A. R. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-0999-2 · Cited by 47
Effects of antiresorptive treatment on nonvertebral fracture outcomes
Mackey, D. C., Black, D. M., Bauer, D. C., McCloskey, E. V., Eastell, R., Mesenbrink, P. G., Thompson, J. R., & Cummings, S. R. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.446 · Cited by 46
Self-citationChiba, M., Tsuji, T., Nakane, K., Tsuda, S., Ishii, H., Ohno, H., Watanabe, K., Ito, M., Komatsu, M., & Sugawara, T. (2017) · The Permanente Journal · doi:10.7812/tpp/17-009 · Cited by 46
Regulation of Hedgehog signaling Offers A Novel Perspective for Bone Homeostasis Disorder Treatment
Lv, W.-T., Du, D., Gao, R., Yu, C. W., Jia, Y., Jia, Z., & Wang, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163981 · Cited by 45
Nyström, A., Kiritopoulos, D., Ullmark, G., Sørensen, J., Petrén‐Mallmin, M., Milbrink, J., Hailer, N. P., & Mallmin, H. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3883 · Cited by 47
Osteoprotegerin: A Biomarker With Many Faces
Caidahl, K., Ueland, T., & Aukrust, P. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.208843 · Cited by 46
Management of osteoporosis in men on androgen deprivation therapy
Adler, R. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.11.003 · Cited by 45
Medication-related osteonecrosis of the jaw: An update
Bansal, H. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_236_20 · Cited by 45
Screening for Osteoporosis to Prevent Fractures
Kahwati, L. C., Kistler, C. E., Booth, G., Sathe, N. A., Gordon, R. D., Okah, E. D., Wines, R., & Viswanathan, M. (2025) · JAMA · doi:10.1001/jama.2024.21653 · Cited by 47
SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease
Mason, J. J., & Williams, B. O. (2010) · Journal of Osteoporosis · doi:10.4061/2010/460120 · Cited by 46
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates
Ristow, O., Gerngroß, C., Schwaiger, M., Hohlweg‐Majert, B., Kehl, V., Jansen, H., Hahnefeld, L., Koerdt, S., Otto, S., & Pautke, C. (2014) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2014.01.021 · Cited by 45
Denosumab for Post-Transplantation Hypercalcemia in Osteopetrosis
Shroff, R. C., Beringer, O., Rao, K., Hofbauer, L. C., & Schulz, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1206193 · Cited by 45
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 47
Pulkkinen, P., Glüer, C., & Jämsä, T. J. (2011) · Bone · doi:10.1016/j.bone.2011.07.022 · Cited by 45
Aortic stenosis: insights on pathogenesis and clinical implications.
Carità, P., Coppola, G., Novo, G., Caccamo, G., Guglielmo, M., Balasus, F., Novo, S., Castrovinci, S., Moscarelli, M., Fattouch, K., et al. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.06.001 · Cited by 45
Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety
Gopaul, A., Kanagalingam, T., Thain, J., Khan, T., Cowan, A., Sultan, N., & Clemens, K. K. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00971-0 · Cited by 45
Denosumab for Low Bone Mass in Hemodialysis Patients: A Noncontrolled Trial
Hiramatsu, R., Ubara, Y., Sawa, N., Hoshino, J., Hasegawa, E., Kawada, M., Imafuku, A., Sumida, K., Mise, K., Hayami, N., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.012 · Cited by 44
Osteoporosis Diagnosis and Medical Treatment
Warriner, A. H., & Saag, K. G. (2013) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.01.005 · Cited by 44
Denosumab for the treatment of osteoporosis: A systematic literature review
Silva-Fernández, L., Rosario, M. P., Martínez-López, J. A., Carmona, L., & Loza, E. (2013) · Reumatología Clínica · doi:10.1016/j.reuma.2012.06.007 · Cited by 45
DEVECİ, M. A., Paydaş, S., Gönlüşen, G., Özkan, C., Biçer, Ö. S., & Tekin, M. (2016) · Acta Orthopaedica et Traumatologica Turcica · doi:10.1016/j.aott.2016.03.004 · Cited by 46
Recent advances in the management of osteoporosis
Fukumoto, S., & Matsumoto, T. (2017) · F1000Research · doi:10.12688/f1000research.10682.1 · Cited by 44
Migliaccio, S., Francomano, D., Romagnoli, E., Marocco, C., Fornari, R., Resmini, G., Buffa, A., Pietro, G. D., Corvaglia, S., Gimigliano, F., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0701-3 · Cited by 44
Addressing the crisis in the treatment of osteoporosis
Roux, C., & Briot, K. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.218 · Cited by 44
Understanding osteoporotic pain and its pharmacological treatment
Vellucci, R., Terenzi, R., Kanis, J. A., Kress, H. G., Mediati, R. D., Reginster, J., Rizzoli, R., & Brandi, M. L. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4476-y · Cited by 46
Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL
Clar, K. L., Hinterleitner, C., Schneider, P., Salih, H. R., & Maurer, S. (2019) · Cancers · doi:10.3390/cancers11030277 · Cited by 44
Zhang, Y., Yang, K., Yang, J., Lao, Y., Deng, L., Deng, G., Yi, J., Sun, X., & Wang, Q. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.036 · Cited by 44
Reproducibility of Results in Preclinical Studies: A Perspective From the Bone Field
Manolagas, S. C., & Kronenberg, H. M. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2293 · Cited by 43
Physiology and pathophysiology of the RANKL/RANK system
Hanada, R., Hanada, T., & Penninger, J. M. (2010) · Biological Chemistry · doi:10.1515/bc.2010.149 · Cited by 43
Prevalence and risk factors of vertebral compression fractures in female SLE patients
Almehed, K., Hetenyi, S., Ohlsson, C., Carlsten, H., & Forsblad‐d’Elia, H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3104 · Cited by 43
Davenport, C., Harper, E., Forde, H. E., Rochfort, K. D., Murphy, R. P., Smith, D., & Cummins, P. M. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.06.009 · Cited by 43
Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
McClung, M. R., Lippuner, K., Brandi, M. L., Zanchetta, J., Bone, H. G., Chapurlat, R. D., Hans, D. B., Wang, A., Zapalowski, C., & Libanati, C. R. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4140-y · Cited by 43
Self-citationCombination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
Bakhru, P., Zhu, M., Wang, H., Hong, L. K., Khan, I. S., Mouchess, M. L., Gulati, A., Starmer, J., Hou, Y., Sailer, D., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93265 · Cited by 44
Chen, Q., Hu, C., Liu, Y., Song, R., Zhu, W., Zhao, H., Nino, A., Zhang, F., & Liu, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197984 · Cited by 43
Choi, S. T., Kwon, S., Jung, J.-Y., Kim, H., Kim, S.-S., Kim, S.-H., Kim, J., Park, J. H., & Suh, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120507 · Cited by 44
Crandall, C. J., Schousboe, J. T., Morin, S. N., Lix, L. M., & Leslie, W. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3717 · Cited by 43
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00924 · Cited by 43
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis
Simon, J. A., Recknor, C. P., Moffett, A. H., Adachi, J. D., Franek, E., Lewiecki, E. M., McClung, M. R., Mautalén, C., Ragi-Eis, S., Nicholson, G. C., et al. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318267f909 · Cited by 43
Self-citationSiddique, M. M., Frost, M. L., Blake, G. M., Moore, A. E. B., Al-Beyatti, Y., Marsden, P. K., Schleyer, P. J., & Fogelman, I. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.093195 · Cited by 43
Stein, M., Elefteriou, F., Busse, B., Fiedler, I. A., Kwon, R. Y., Farrell, E., Ahmad, M., Ignatius, A., Grover, L., Geris, L., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4868 · Cited by 42
Osteoporosis - new treatments and updates.
Honig, S. (2010) · PubMed · Cited by 42
Sun, Q., Tian, F., Liu, F., Fang, J.-K., Hu, Y., Lian, Q., Zhou, Z., & Zhang, L. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02525-8 · Cited by 42
Cowan, A., Jeyakumar, N., McArthur, E., Fleet, J. L., Kanagalingam, T., Karp, I., Khan, T., Muanda, F. T., Nash, D. M., Silver, S. A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4804 · Cited by 42
New Approaches to the Treatment of Osteoporosis
Silva, B. C. C., & Bilezikian, J. P. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-061709-145401 · Cited by 42
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
Hiligsmann, M., & Reginster, J. (2010) · Bone · doi:10.1016/j.bone.2010.03.009 · Cited by 42
Economic burden of osteoporotic fractures in Austria
Dimai, H. P., Redlich, K., Peretz, M., Borgström, F., Siebert, U., & Mahlich, J. (2012) · Health Economics Review · doi:10.1186/2191-1991-2-12 · Cited by 42
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 43
Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro
Ogata, K., Katagiri, W., & Hibi, H. (2016) · Clinical Oral Investigations · doi:10.1007/s00784-016-1986-x · Cited by 43
The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease
Makino, T., Tsukazaki, H., Ukon, Y., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082430 · Cited by 44
Importance of Recent Fracture as Predictor of Imminent Fracture Risk
Schnell, A., Curtis, J. R., & Saag, K. G. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0487-z · Cited by 42
Ensrud, K. E., Kats, A. M., Boyd, C. M., Diem, S. J., Schousboe, J. T., Taylor, B. C., Bauer, D. C., Stone, K. L., & Langsetmo, L. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0682 · Cited by 44
Medical treatment of osteoporosis
Palacios, S. (2021) · Climacteric · doi:10.1080/13697137.2021.1951697 · Cited by 47
Li, M., Fu, S., Cai, Z., Li, D., Liu, L., Deng, D., Jin, R., & Ai, H. (2021) · Regenerative Biomaterials · doi:10.1093/rb/rbab027 · Cited by 42
Bone mineral density and prediction of non-osteoporotic disease
Trémollières, F., & Ribot, C. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.023 · Cited by 42
Bone mineral loss at the proximal femur in acute spinal cord injury
Edwards, W. B., Schnitzer, T. J., & Troy, K. L. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2323-8 · Cited by 45
Balancing benefits and risks in the era of biologics
Adami, G., Saag, K. G., Chapurlat, R. D., Guañabens, N., Haugeberg, G., Lems, W. F., Matijević, R., Peel, N. F. A., Poddubnyy, D., & Geusens, P. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19883973 · Cited by 42
Gates, M., Pillay, J., Nuspl, M., Wingert, A., Vandermeer, B., & Hartling, L. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02181-w · Cited by 46
Kostenuik, P. J., Smith, S. Y., Samadfam, R., Jolette, J., Zhou, L., & Ominsky, M. S. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2401 · Cited by 41
New Treatment Modalities in Osteoporosis
CANALIS, E. M. (2010) · Endocrine Practice · doi:10.4158/ep10048.ra · Cited by 42
Denosumab for the management of bone disease in patients with solid tumors
Body, J. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.204 · Cited by 40
The Case for Routine Parathyroid Hormone Monitoring
Sprague, S. M., & Moe, S. M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04650512 · Cited by 41
Metadata
- Authors
- Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., & Christiansen, C.
- Affiliations
- University of California, San Francisco (US)
- Columbia University Irving Medical Center (US)
- University of Sheffield (GB)
- University of Auckland (NZ)
- Inserm (FR)
- Amgen (United States) (US)
- University of Verona (IT)
- Center for Clinical & Basic Research (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-20
- Volume
- 361
- Issue
- 8
- Pages
- 756-765
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160005424
- Cited by
- 3,489
- References
- 39
- Citations by year
- 2026: 187 · 2025: 220 · 2024: 203 · 2023: 164 · 2022: 226 · 2021: 210 · 2020: 223 · 2019: 200 · 2018: 208 · 2017: 195 · 2016: 180 · 2015: 238 · 2014: 168 · 2013: 222 · 2012: 197
- FWCI
- 223.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- denosumab, osteoporosis, postmenopausal women, fracture prevention, RANKL inhibition, vertebral fractures, hip fracture, non-vertebral fractures, bone mineral density, monoclonal antibodies, osteoclasts, bone resorption, adverse events, osteonecrosis of the jaw, hypocalcemia, cancer risk, cardiovascular risk
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Hip Fractures, Humans, Middle Aged, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
